1
|
Frances L, Croyal M, Ruidavets JB, Maraninchi M, Combes G, Raffin J, de Souto Barreto P, Ferrières J, Blaak EE, Perret B, Moro C, Valéro R, Martinez LO, Viguerie N. Identification of circulating apolipoprotein M as a new determinant of insulin sensitivity and relationship with adiponectin. Int J Obes (Lond) 2024:10.1038/s41366-024-01510-w. [PMID: 38491190 DOI: 10.1038/s41366-024-01510-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Revised: 02/28/2024] [Accepted: 03/05/2024] [Indexed: 03/18/2024]
Abstract
BACKGROUND The adiponectin is one of the rare adipokines down-regulated with obesity and protects against obesity-related disorders. Similarly, the apolipoprotein M (apoM) is expressed in adipocytes and its expression in adipose tissue is associated with metabolic health. We compared circulating apoM with adiponectin regarding their relationship with metabolic parameters and insulin sensitivity and examined their gene expression patterns in adipocytes and in the adipose tissue. METHODS Circulating apoM and adiponectin were examined in 169 men with overweight in a cross-sectional study, and 13 patients with obesity during a surgery-induced slimming program. Correlations with clinical parameters including the insulin resistance index (HOMA-IR) were analyzed. Multiple regression analyses were performed on HOMA-IR. The APOM and ADIPOQ gene expression were measured in the adipose tissue from 267 individuals with obesity and a human adipocyte cell line. RESULTS Participants with type 2 diabetes had lower circulating adiponectin and apoM, while apoM was higher in individuals with dyslipidemia. Similar to adiponectin, apoM showed negative associations with HOMA-IR and hs-CRP (r < -0.2), and positive correlations with HDL markers (HDL-C and apoA-I, r > 0.3). Unlike adiponectin, apoM was positively associated with LDL markers (LDL-C and apoB100, r < 0.20) and negatively correlated with insulin and age (r < -0.2). The apoM was the sole negative determinant of HOMA-IR in multiple regression models, while adiponectin not contributing significantly. After surgery, the change in HOMA-IR was negatively associated with the change in circulating apoM (r = -0.71), but not with the change in adiponectin. The APOM and ADIPOQ gene expression positively correlated in adipose tissue (r > 0.44) as well as in adipocytes (r > 0.81). In adipocytes, APOM was downregulated by inflammatory factors and upregulated by adiponectin. CONCLUSIONS The apoM rises as a new partner of adiponectin regarding insulin sensitivity. At the adipose tissue level, the adiponectin may be supported by apoM to promote a healthy adipose tissue. TRIAL REGISTRATION NCT01277068, registered 13 January 2011; NCT02332434, registered 5 January 2015; and NCT00390637, registered 20 October 2006.
Collapse
Affiliation(s)
- Laurie Frances
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, 31432, Toulouse, France
| | - Mikaël Croyal
- Nantes Université, CHU Nantes, CNRS, INSERM, BioCore, US16, SFR Bonamy, 44000, Nantes, France
- CRNH-Ouest Mass Spectrometry Core Facility, 44000, Nantes, France
- Nantes Université, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44000, Nantes, France
| | | | - Marie Maraninchi
- Aix Marseille Université, APHM, INSERM, INRAe, C2VN, Department of Nutrition, Metabolic Diseases and Endocrinology, University Hospital La Conception, 13385, Marseille, France
| | - Guillaume Combes
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, 31432, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, IHU HealthAge, Inserm, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France
| | - Jérémy Raffin
- Institut Hospitalo-Universitaire HealthAge, IHU HealthAge, Inserm, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France
- Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, 31000, Toulouse, France
| | - Philippe de Souto Barreto
- CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, 31000, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, IHU HealthAge, Inserm, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France
- Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, 31000, Toulouse, France
| | - Jean Ferrières
- CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, 31000, Toulouse, France
- Department of Cardiology, Toulouse Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France
| | - Ellen E Blaak
- Department of Human Biology, NUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+(MUMC+), Maastricht, The Netherlands
| | - Bertrand Perret
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, 31432, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, IHU HealthAge, Inserm, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France
| | - Cédric Moro
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, 31432, Toulouse, France
| | - René Valéro
- Aix Marseille Université, APHM, INSERM, INRAe, C2VN, Department of Nutrition, Metabolic Diseases and Endocrinology, University Hospital La Conception, 13385, Marseille, France
| | - Laurent O Martinez
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, 31432, Toulouse, France.
- Institut Hospitalo-Universitaire HealthAge, IHU HealthAge, Inserm, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
| | - Nathalie Viguerie
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, 31432, Toulouse, France.
| |
Collapse
|
2
|
Duparc T, Gore E, Combes G, Beuzelin D, Pires Da Silva J, Bouguetoch V, Marquès MA, Velazquez A, Viguerie N, Tavernier G, Arner P, Rydén M, Langin D, Sioufi N, Nasser M, Cabou C, Najib S, Martinez LO. P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease. JCI Insight 2024; 9:e175623. [PMID: 38470490 DOI: 10.1172/jci.insight.175623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 03/05/2024] [Indexed: 03/13/2024] Open
Abstract
Excessive lipolysis in white adipose tissue (WAT) leads to insulin resistance (IR) and ectopic fat accumulation in insulin-sensitive tissues. However, the impact of Gi-coupled receptors in restraining adipocyte lipolysis through inhibition of cAMP production remained poorly elucidated. Given that the Gi-coupled P2Y13 receptor (P2Y13-R) is a purinergic receptor expressed in WAT, we investigated its role in adipocyte lipolysis and its effect on IR and metabolic dysfunction-associated steatotic liver disease (MASLD). In humans, mRNA expression of P2Y13-R in WAT was negatively correlated to adipocyte lipolysis. In mice, adipocytes lacking P2Y13-R displayed higher intracellular cAMP levels, indicating impaired Gi signaling. Consistently, the absence of P2Y13-R was linked to increased lipolysis in adipocytes and WAT explants via hormone-sensitive lipase activation. Metabolic studies indicated that mice lacking P2Y13-R showed a greater susceptibility to diet-induced IR, systemic inflammation, and MASLD compared with their wild-type counterparts. Assays conducted on precision-cut liver slices exposed to WAT conditioned medium and on liver-specific P2Y13-R-knockdown mice suggested that P2Y13-R activity in WAT protects from hepatic steatosis, independently of liver P2Y13-R expression. In conclusion, our findings support the idea that targeting adipose P2Y13-R activity may represent a pharmacological strategy to prevent obesity-associated disorders, including type 2 diabetes and MASLD.
Collapse
Affiliation(s)
- Thibaut Duparc
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Emilia Gore
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Guillaume Combes
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| | - Diane Beuzelin
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Lifesearch SAS, Toulouse, France
| | - Julie Pires Da Silva
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Vanessa Bouguetoch
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
- Lifesearch SAS, Toulouse, France
| | | | - Ana Velazquez
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Nathalie Viguerie
- MetaDiab, I2MC, University of Toulouse, INSERM, UPS, UMR1297, Toulouse, France
| | - Geneviève Tavernier
- MetaDiab, I2MC, University of Toulouse, INSERM, UPS, UMR1297, Toulouse, France
| | - Peter Arner
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Mikael Rydén
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - Dominique Langin
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
- MetaDiab, I2MC, University of Toulouse, INSERM, UPS, UMR1297, Toulouse, France
- Biochemistry Laboratory, Toulouse University Hospital, Toulouse, France
- Institut Universitaire de France (IUF), Paris, France
| | - Nabil Sioufi
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
- Lifesearch SAS, Toulouse, France
| | - Mohamad Nasser
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| | - Cendrine Cabou
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| | - Souad Najib
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| | - Laurent O Martinez
- LiMitAging, Institute of Metabolic and Cardiovascular Diseases (I2MC), University of Toulouse, INSERM, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
- Institut Hospitalo-Universitaire HealthAge, (IHU HealthAge), INSERM, Toulouse University Hospital, Toulouse, France
| |
Collapse
|
3
|
Raffin J, Rolland Y, Genoux A, Combes G, Croyal M, Perret B, Guyonnet S, Vellas B, Martinez LO, de Souto Barreto P. Associations between physical activity levels and ATPase inhibitory factor 1 concentrations in older adults. J Sport Health Sci 2023:S2095-2546(23)00094-7. [PMID: 37748689 DOI: 10.1016/j.jshs.2023.09.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 05/19/2023] [Accepted: 08/28/2023] [Indexed: 09/27/2023]
Abstract
BACKGROUND Adenosine triphosphatase inhibitory factor 1 (IF1) is a key protein involved in energy metabolism. IF1 has been linked to various age-related diseases, although its relationship with physical activity (PA) remains unclear. Additionally, the apolipoprotein A-I (apoA-I), a PA-modulated lipoprotein could play a role in this relationship because it shares a binding site with IF1 on the cell-surface ATP synthase. We examined here the associations between chronic PA and plasma IF1 concentrations among older adults, and we investigated whether apoA-I mediated these associations. METHODS In the present work, 1096 healthy adults (63.8% women) aged 70 years and over who were involved in the Multidomain Alzheimer Prevention Trial study were included. IF1 plasma concentrations (square root of ng/mL) were measured at the 1-year visit of the Multidomain Alzheimer Prevention Trial, while PA levels (square root of metabolic equivalent task min/week) were assessed using questionnaires administered each year from baseline to the 3-year visit. Multiple linear regressions were performed to investigate the associations between the first-year mean PA levels and IF1 concentrations. Mediation analyses were conducted to examine whether apoA-I mediated these associations. Mixed-effect linear regressions were carried out to investigate whether the 1-year visit IF1 concentrations predicted subsequent changes in PA. RESULTS Multiple linear regressions indicated that first-year mean PA levels were positively associated with IF1 concentrations (B = 0.021; SE = 0.010; p = 0.043). Mediation analyses revealed that about 37.7% of this relationship was mediated by apoA-I (Bab = 0.008; SE = 0.004; p = 0.023). Longitudinal investigations demonstrated that higher concentrations of IF1 at the 1-year visit predicted a faster decline in PA levels over the subsequent 2 years (time × IF1: B = -0.148; SE = 0.066; p = 0.025). CONCLUSION This study demonstrated that regular PA is associated with plasma IF1 concentrations, and it suggests that apoA-I partly mediates this association. Additionally, this study found that baseline concentrations of IF1 can predict future changes in PA. However, further research is needed to fully understand the mechanisms underlying these observations.
Collapse
Affiliation(s)
- Jérémy Raffin
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse 31000, France.
| | - Yves Rolland
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse 31000, France; Centre d'Epidémiologie et de Recherche en Santé des Populations, Unité Mixte de Recherche 1295, Institut National de la Santé et de la Recherche Médicale, Université Toulouse-III-Paul-Sabatier, Toulouse 31000, France
| | - Annelise Genoux
- LimitAging Team, Institut des Maladies Métaboliques et Cardiovasculaires, Unité Mixte de Recherche 1297, Institut National de la Santé et de la Recherche Médicale, Université Toulouse III - Paul Sabatier, Toulouse Cedex 4, 31432, France; Service de Biochimie, Pôle de biologie, Hôpital de Purpan, Centre Hospitalo-Universitaire de Toulouse, Toulouse 31300, France
| | - Guillaume Combes
- LimitAging Team, Institut des Maladies Métaboliques et Cardiovasculaires, Unité Mixte de Recherche 1297, Institut National de la Santé et de la Recherche Médicale, Université Toulouse III - Paul Sabatier, Toulouse Cedex 4, 31432, France
| | - Mikael Croyal
- L'Institut du Thorax, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Centre Hospitalo-Universitaire de Nantes, Nantes Université, Nantes 44000, France; BioCore, US16, Structure Fédérative de Recherche Bonamy, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Centre Hospitalo-Universitaire de Nantes, Nantes Université, Nantes 44000, France; Plate-forme de spectrométrie de masse, Centre de Recherche en Nutrition HumaineOuest, Nantes 44000, France
| | - Bertrand Perret
- LimitAging Team, Institut des Maladies Métaboliques et Cardiovasculaires, Unité Mixte de Recherche 1297, Institut National de la Santé et de la Recherche Médicale, Université Toulouse III - Paul Sabatier, Toulouse Cedex 4, 31432, France; Service de Biochimie, Pôle de biologie, Hôpital de Purpan, Centre Hospitalo-Universitaire de Toulouse, Toulouse 31300, France
| | - Sophie Guyonnet
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse 31000, France; Centre d'Epidémiologie et de Recherche en Santé des Populations, Unité Mixte de Recherche 1295, Institut National de la Santé et de la Recherche Médicale, Université Toulouse-III-Paul-Sabatier, Toulouse 31000, France
| | - Bruno Vellas
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse 31000, France; Centre d'Epidémiologie et de Recherche en Santé des Populations, Unité Mixte de Recherche 1295, Institut National de la Santé et de la Recherche Médicale, Université Toulouse-III-Paul-Sabatier, Toulouse 31000, France
| | - Laurent O Martinez
- LimitAging Team, Institut des Maladies Métaboliques et Cardiovasculaires, Unité Mixte de Recherche 1297, Institut National de la Santé et de la Recherche Médicale, Université Toulouse III - Paul Sabatier, Toulouse Cedex 4, 31432, France.
| | - Philipe de Souto Barreto
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse 31000, France; Centre d'Epidémiologie et de Recherche en Santé des Populations, Unité Mixte de Recherche 1295, Institut National de la Santé et de la Recherche Médicale, Université Toulouse-III-Paul-Sabatier, Toulouse 31000, France
| |
Collapse
|
4
|
Mérian J, Ghezali L, Trenteseaux C, Duparc T, Beuzelin D, Bouguetoch V, Combes G, Sioufi N, Martinez LO, Najib S. Intermittent Fasting Resolves Dyslipidemia and Atherogenesis in Apolipoprotein E-Deficient Mice in a Diet-Dependent Manner, Irrespective of Sex. Cells 2023; 12:cells12040533. [PMID: 36831200 PMCID: PMC9953823 DOI: 10.3390/cells12040533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 01/30/2023] [Accepted: 02/03/2023] [Indexed: 02/11/2023] Open
Abstract
In humans and animal models, intermittent fasting (IF) interventions promote body weight loss, improve metabolic health, and are thought to lower cardiovascular disease risk. However, there is a paucity of reports on the relevance of such nutritional interventions in the context of dyslipidemia and atherosclerotic cardiovascular diseases. The present study assessed the metabolic and atheroprotective effects of intermittent fasting intervention (IF) in atherosclerosis-prone apolipoprotein E-deficient (Apoe-/-) mice. Groups of male and female Apoe-/- mice were fed a regular (chow) or atherogenic (high-fat, high-cholesterol, HFCD) diet for 4 months, either ad libitum or in an alternate-day fasting manner. The results show that IF intervention improved glucose and lipid metabolism independently of sex. However, IF only decreased body weight gain in males fed chow diet and differentially modulated adipose tissue parameters and liver steatosis in a diet composition-dependent manner. Finally, IF prevented spontaneous aortic atherosclerotic lesion formation in mice fed chow diet, irrespective of sex, but failed to reduce HFCD-diet-induced atherosclerosis. Overall, the current work indicates that IF interventions can efficiently improve glucose homeostasis and treat atherogenic dyslipidemia, but a degree of caution is warranted with regard to the individual sex and the composition of the dietary regimen.
Collapse
Affiliation(s)
- Jules Mérian
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III—Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
| | - Lamia Ghezali
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III—Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
- Lifesearch SAS, 195 Route d’Espagne, 31100 Toulouse, France
| | - Charlotte Trenteseaux
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III—Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
- Lifesearch SAS, 195 Route d’Espagne, 31100 Toulouse, France
| | - Thibaut Duparc
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III—Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
| | - Diane Beuzelin
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III—Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
- Lifesearch SAS, 195 Route d’Espagne, 31100 Toulouse, France
| | - Vanessa Bouguetoch
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III—Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
- Lifesearch SAS, 195 Route d’Espagne, 31100 Toulouse, France
| | - Guillaume Combes
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III—Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
| | - Nabil Sioufi
- Lifesearch SAS, 195 Route d’Espagne, 31100 Toulouse, France
| | - Laurent O. Martinez
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III—Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
| | - Souad Najib
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III—Paul Sabatier (UPS), UMR1297, 31432 Toulouse, France
- Correspondence: ; Tel.: +33-531-224-082
| |
Collapse
|
5
|
Pires Da Silva J, Wargny M, Raffin J, Croyal M, Duparc T, Combes G, Genoux A, Perret B, Vellas B, Guyonnet S, Thalamas C, Langin D, Moro C, Viguerie N, Rolland Y, Barreto PDS, Cariou B, Martinez LO. Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study. Diabetes Metab 2023; 49:101391. [PMID: 36174852 DOI: 10.1016/j.diabet.2022.101391] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 09/15/2022] [Accepted: 09/22/2022] [Indexed: 01/28/2023]
Abstract
AIM Mitochondrial dysfunction is associated with the development of type 2 diabetes mellitus (T2DM). It is thus of clinical relevance to identify plasma biomarkers of mitochondrial dysfunction associated with the risk of T2DM. ATPase inhibitory factor 1 (IF1) endogenously inhibits mitochondrial ATP synthase activity. Here, we analyzed association of the plasma IF1 level with markers of glucose homeostasis and with the conversion to new-onset diabetes (NOD) in individuals with prediabetes. METHODS In the IT-DIAB prospective study, the baseline plasma level of IF1 was measured in 307 participants with prediabetes. The primary outcome was the incidence of NOD within five years of follow-up. Cross-sectional analysis of the IF1 level was also done in two independent interventional studies. Correlations between plasma IF1 and metabolic parameters at baseline were assessed by Spearman's correlation coefficients, and the association with the risk of NOD was determined using Cox proportional-hazards models. RESULTS In IT-DIAB, the mean IF1 plasma level was lower in participants who developed NOD than in those who did not (537 ± 248 versus 621 ± 313 ng/mL, P = 0.01). The plasma IF1 level negatively correlated with clinical variables associated with obesity and insulin resistance, including the body mass index (r = -0.20, P = 0.0005) and homeostasis model assessment of insulin resistance (HOMA-IR). (r = -0.37, P < 0.0001). Conversely, IF1 was positively associated with plasma markers of cardiometabolic health, such as HDL-C (r = 0.63, P < 0.0001) and apoA-I (r = 0.33, P < 0.0001). These correlations were confirmed in cross-sectional analyses. In IT-DIAB, the IF1 level was significantly associated with a lower risk of T2DM after adjustment for age, sex, and fasting plasma glucose (HR [95% CI] per 1 SD = 0.76 [0.62; 0.94], P = 0.012). CONCLUSION We identified for the first time the mitochondrial-related biomarker IF1 as being associated with the risk of T2DM.
Collapse
Affiliation(s)
- Julie Pires Da Silva
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Matthieu Wargny
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, 44000 Nantes, France; Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11 : Santé Publique, Clinique des données, INSERM, CIC 1413, F-44000 Nantes, France
| | - Jérémy Raffin
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France
| | - Mikaël Croyal
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, 44000 Nantes, France; Nantes Université, CHU Nantes, CNRS, Inserm, BioCore, US16, SFR Bonamy, F-44000 Nantes, France; CRNH-Ouest Mass Spectrometry Core Facility, 44000 Nantes, France
| | - Thibaut Duparc
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Guillaume Combes
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Annelise Genoux
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France; Service de Biochimie, Pôle de biologie, Hôpital de Purpan, CHU de Toulouse, Toulouse, France
| | - Bertrand Perret
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France; Service de Biochimie, Pôle de biologie, Hôpital de Purpan, CHU de Toulouse, Toulouse, France
| | - Bruno Vellas
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France; CERPOP UMR 1295, University of Toulouse III, INSERM, UPS, Toulouse, France
| | - Sophie Guyonnet
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France; CERPOP UMR 1295, University of Toulouse III, INSERM, UPS, Toulouse, France
| | - Claire Thalamas
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France; Clinical Investigation Center, Université de Toulouse, INSERM, Université Toulouse III-Paul Sabatier, Toulouse University Hospitals, CIC1436, F-CRIN/FORCE Network, Toulouse, France
| | - Dominique Langin
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France; Service de Biochimie, Pôle de biologie, Hôpital de Purpan, CHU de Toulouse, Toulouse, France; Institut Universitaire de France (IUF), Paris, France
| | - Cédric Moro
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Nathalie Viguerie
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France
| | - Yves Rolland
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France; CERPOP UMR 1295, University of Toulouse III, INSERM, UPS, Toulouse, France
| | - Philipe de Souto Barreto
- Institut du Vieillissement, Gérontopôle de Toulouse, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France; CERPOP UMR 1295, University of Toulouse III, INSERM, UPS, Toulouse, France
| | - Bertrand Cariou
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du Thorax, 44000 Nantes, France
| | - Laurent O Martinez
- Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III - Paul Sabatier (UPS), UMR1297, Toulouse, France.
| | -
- Members are listed in the acknowledgements
| |
Collapse
|
6
|
Horckmans M, Diaz Villamil E, Verdier C, Laurell H, Ruidavets JB, De Roeck L, Combes G, Martinez LO, Communi D. Loss-of-function N178T variant of the human P2Y4 receptor is associated with decreased severity of coronary artery disease and improved glucose homeostasis. Front Pharmacol 2022; 13:1049696. [DOI: 10.3389/fphar.2022.1049696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Accepted: 11/22/2022] [Indexed: 12/04/2022] Open
Abstract
Human P2Y4 is a UTP receptor, while in mice it is activated by both ATP and UTP. P2Y4 knockout (KO) in mice protects against myocardial infarction and is characterized by increased adiponectin secretion by adipocytes, and decreased cardiac inflammation and permeability under ischemic conditions. The relevance of these data has, however, not been explored to date in humans. In a population study comprising 50 patients with coronary artery disease (CAD) and 50 age-matched control individuals, we analyzed P2RY4 mutations and their potential association with CAD severity and fasting plasma parameters. Among the mutations identified, we focused our attention on a coding region polymorphism (rs3745601) that results in replacement of the asparagine at residue 178 with threonine (N178T) located in the second extracellular loop of the P2Y4 receptor. The N178T variant is a loss-of-function mutation of the human P2Y4 receptor and is encountered less frequently in coronary patients than in control individuals. In coronary patients, carriers of the N178T variant had significantly reduced jeopardy and Gensini cardiac severity scores, as well as lower resting heart rates and plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP). Regarding fasting plasma parameters, the N178T variant was associated with a lower concentration of glucose. Accordingly, P2Y4 KO mice had significantly improved glucose tolerance and insulin sensitivity compared with their WT littermate controls. The improvement of insulin sensitivity resulting from lack of the P2Y4 receptor was no longer observed in the absence of adiponectin. The present study identifies a frequent loss-of-function P2Y4 variant associated with less severe coronary artery atherosclerosis and lower fasting plasma glucose in coronary patients. The role of the P2Y4 receptor in glucose homeostasis was confirmed in mouse. P2Y4 antagonists could thus have therapeutic applications in the treatment of myocardial infarction and type 2 diabetes.
Collapse
|
7
|
Martinez L, Gore E, Combes G, Cabou C, Duparc T. The GI-coupled P2Y13 receptor signaling inhibits lipolysis and protects from metabolic syndrome and associated liver diseases. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
8
|
O’Connell Francischetto E, Jones J, Allen K, Combes G, Damery S. 683 UNDERSTANDING HOW DISCHARGE SERVICES FOR OLDER PATIENTS CAN BRIDGE THE GAP BETWEEN HOSPITAL, COMMUNITY AND SOCIAL CARE. Age Ageing 2022. [DOI: 10.1093/ageing/afac035.683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
UK policy recommends that discharge support is provided by hospital, community and social care staff. However, there is a lack of understanding regarding how these multiagency hospital discharge services work in practice, how they can be sustained and what service stakeholder experiences of them are. This research aimed to understand how integrated discharge services work and the views and experiences of stakeholders.
Method
A qualitative case study of a supported integrated hospital discharge service (SIHDS) for older people was undertaken, which involved interviews with service staff (hospital, community and social care), patients and carers. Staff, patients and carers were interviewed on their experiences of SIHDS. Staff also took part in a process mapping exercise to understand how the service works. Interviews were analysed using thematic analysis. Ethical approval was obtained for this research.
Results
A variety of staff (n = 14) and patients aged over 60 years (n = 11) and their informal carers/family members (n = 4) were interviewed. Three main staff themes emerged from the findings: 1. Preparedness for discharge and impact of discharge service; 2. Integration and impact on patient pathway and 3. Organisational aspects. The three main patient/carer themes were: 1. Support for patients; 2. Patient Outcomes and 3. Information exchange. The findings demonstrated that: SIHDS was seen as important to allow patients to be discharged home in a timely and safe manner; that communication is important at all levels of a SIHDS and SIHDS need to continuously evolve to provide patient centred care.
Conclusion
The findings from this qualitative case study allow the complexities involved in SIHDS to be understood from the experiences and perspectives of multiagency staff, patients and carers. It shows SIHDS are complex, but useful to overcome gaps between services. However, to effectively sustain a patient centred service it is important to regularly review and develop SIHDS.
Collapse
Affiliation(s)
- E O’Connell Francischetto
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| | - J Jones
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| | - K Allen
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| | - G Combes
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| | - S Damery
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| |
Collapse
|
9
|
O’Connell Francischetto E, Jones J, Davies S, Allen K, Combes G, Damery S. 682 IMPACT OF DISCHARGE INTERVENTIONS FOR OLDER PATIENTS LEAVING HOSPITAL: A SYSTEMATIC REVIEW OF REVIEWS. Age Ageing 2022. [DOI: 10.1093/ageing/afac036.682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The UK has an aging population and there is an increasing need for additional care and support services for elderly patients discharged from hospital. Despite a large evidence base on different discharge services there is inconsistent findings on their effectiveness. This systematic review of reviews aimed to evaluate the impact of a variety of discharge interventions on older people leaving hospital.
Method
Ten databases were searched (including Medline and The Cochrane Library) using multiple key search terms related to ‘systematic reviews’, ‘older people’ and ‘discharge’. Only systematic reviews of interventions for people aged over 60 years that provided additional support or adapted their discharge processes were included. Outcomes of interest included mortality, readmissions, length of hospital stay, patient health status and costs. Abstract, title and full-text screening was conducted independently by two reviewers. Interventions were categorised by intervention type and a narrative synthesis was conducted on data extracted.
Results
Of the 8,748 title and abstracts reviewed, 859 full texts were assessed for eligibility, of these 91 were taken forward to quality assessment and 66 moderate or high-quality reviews were included in the final synthesis. Interventions were categorised into 10 types and had varying impact on outcomes. A statistically significant positive impact on the outcomes of interest was found for: Interventions providing ‘rehabilitation, therapy or care at home (or in the community) around the time of discharge’ reducing length of stay; ‘primary care interventions’, ‘Discharge planning/coordination or case management’ and ‘patient education’.
Conclusion
This systematic review of reviews shows that different types and configurations of discharge interventions can benefit older patients in multiple ways when compared to usual care and highlights which intervention types make no difference or have negative impacts. These findings will help to inform the development of new discharge interventions and the direction of future research.
Collapse
Affiliation(s)
- E O’Connell Francischetto
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Surrey and Sussex Healthcare NHS Trust; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| | - J Jones
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Surrey and Sussex Healthcare NHS Trust; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| | - S Davies
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Surrey and Sussex Healthcare NHS Trust; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| | - K Allen
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Surrey and Sussex Healthcare NHS Trust; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| | - G Combes
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Surrey and Sussex Healthcare NHS Trust; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| | - S Damery
- Prevention, Wellbeing and Communities Hub, Gloucestershire County Council & Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Surrey and Sussex Healthcare NHS Trust; Health Services Management Centre, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham; Applied Research Collaborations (ARC) West Midlands, University of Birmingham
| |
Collapse
|
10
|
Najib S, Trenteseaux C, Merian J, Combes G, Duparc T, Beuzelin D, Martinez L, Ghezali L. Intermittent fasting reduces hypertriglyceridemia and protects against atherosclerosis progression in males and females APOE-/- mice, only under chow diet. Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Duparc T, Briand F, Trenteseaux C, Merian J, Combes G, Najib S, Sulpice T, Martinez LO. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2019; 317:G508-G517. [PMID: 31460789 DOI: 10.1152/ajpgi.00139.2019] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Nonalcoholic steatohepatitis (NASH) is an emerging health problem worldwide. However, efficacious pharmacological treatment for NASH is lacking. A major issue for preclinical evaluation of potential therapeutics for NASH is the limited number of appropriate animal models, i.e., models that do not require long-term dietary intervention and adequately mimic disease progression in humans. The present study aimed to evaluate a 3-wk dietary mouse model of NASH and validate it by studying the effects of liraglutide, a compound in advanced clinical development for NASH. C57BL6/J mice were fed a diet high in fat (60%), cholesterol (1.25%), and cholic acid (0.5%), along with 2% hydroxypropyl-β-cyclodextrin in drinking water (HFCC-CDX diet). Histological and biological parameters were measured at 1 and 3 wk. After 1-wk diet induction, liraglutide was administrated daily for 2 wk and then NASH-associated phenotypic aspects were evaluated in comparison with control mice. Prior to treatment with liraglutide, mice fed the HFCC-CDX diet for 1 wk developed liver steatosis and had increased levels of oxidative-stress markers and hepatic and systemic inflammation. For mice not treated with liraglutide, these aspects were even more pronounced after 3 wk of the dietary period, with additional liver insulin resistance and fibrosis. Liraglutide treatment corrected the diet-induced alterations in glucose metabolism and significantly reduced hepatic steatosis and inflammation. This study provides a novel 3-wk dietary model of mice that rapidly develop NASH features, and this model will be suitable for evaluating the therapeutic efficacy of compounds in preclinical drug development for NASH.NEW & NOTEWORTHY We propose a diet high in fat (60%), cholesterol (1.25%), and cholic acid (0.5%) along with 2% hydroxypropyl-β-cyclodextrin in drinking water (HFCC-CDX diet) as a new dietary model of nonalcoholic steatohepatitis. We used the HFCC-CDX model to reproduce the main features of disease development in humans for the purpose of facilitating the rapid screening of drug candidates and prioritizing the more promising candidates for advanced preclinical assessment and subsequent clinical trials.
Collapse
Affiliation(s)
- Thibaut Duparc
- INSERM, Université de Toulouse, UMR1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), Toulouse, France
| | | | | | - Jules Merian
- INSERM, Université de Toulouse, UMR1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), Toulouse, France
| | - Guillaume Combes
- INSERM, Université de Toulouse, UMR1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), Toulouse, France
| | - Souad Najib
- INSERM, Université de Toulouse, UMR1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), Toulouse, France
| | | | - Laurent O Martinez
- INSERM, Université de Toulouse, UMR1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), Toulouse, France
| |
Collapse
|
12
|
Duparc T, Trenteseaux C, Combes G, Merian J, Ghezalli L, Najib S, Martinez L. Additional Protective Effect Of P2y13 Purinergic Receptor In Cardiometabolic Diseases: Role In Non-Alcoholic Fatty Liver Disease. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
13
|
Picot M, Croyal M, Duparc T, Combes G, Vayssière C, Perret B, Hamdi S, Martinez L, Genoux A. Preeclampsia is associated with changes in the composition and dysfunction of high-density lipoproteins. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2019.05.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Cabou C, Honorato P, Briceño L, Ghezali L, Duparc T, León M, Combes G, Frayssinhes L, Fournel A, Abot A, Masri B, Parada N, Aguilera V, Aguayo C, Knauf C, González M, Radojkovic C, Martinez LO. Pharmacological inhibition of the F 1 -ATPase/P2Y 1 pathway suppresses the effect of apolipoprotein A1 on endothelial nitric oxide synthesis and vasorelaxation. Acta Physiol (Oxf) 2019; 226:e13268. [PMID: 30821416 DOI: 10.1111/apha.13268] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Revised: 02/14/2019] [Accepted: 02/22/2019] [Indexed: 12/12/2022]
Abstract
AIM The contribution of apolipoprotein A1 (APOA1), the major apolipoprotein of high-density lipoprotein (HDL), to endothelium-dependent vasodilatation is unclear, and there is little information regarding endothelial receptors involved in this effect. Ecto-F1 -ATPase is a receptor for APOA1, and its activity in endothelial cells is coupled to adenosine diphosphate (ADP)-sensitive P2Y receptors (P2Y ADP receptors). Ecto-F1 -ATPase is involved in APOA1-mediated cell proliferation and HDL transcytosis. Here, we investigated the effect of lipid-free APOA1 and the involvement of ecto-F1 -ATPase and P2Y ADP receptors on nitric oxide (NO) synthesis and the regulation of vascular tone. METHOD Nitric oxide synthesis was assessed in human endothelial cells from umbilical veins (HUVECs) and isolated mouse aortas. Changes in vascular tone were evaluated by isometric force measurements in isolated human umbilical and placental veins and by assessing femoral artery blood flow in conscious mice. RESULTS Physiological concentrations of lipid-free APOA1 enhanced endothelial NO synthesis, which was abolished by inhibitors of endothelial nitric oxide synthase (eNOS) and of the ecto-F1 -ATPase/P2Y1 axis. Accordingly, APOA1 inhibited vasoconstriction induced by thromboxane A2 receptor agonist and increased femoral artery blood flow in mice. These effects were blunted by inhibitors of eNOS, ecto-F1 -ATPase and P2Y1 receptor. CONCLUSIONS Using a pharmacological approach, we thus found that APOA1 promotes endothelial NO production and thereby controls vascular tone in a process that requires activation of the ecto-F1 -ATPase/P2Y1 pathway by APOA1. Pharmacological targeting of this pathway with respect to vascular diseases should be explored.
Collapse
Affiliation(s)
- Cendrine Cabou
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
- Department of Human Physiology, Faculty of Pharmacy University Paul Sabatier Toulouse France
| | - Paula Honorato
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Luis Briceño
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Lamia Ghezali
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Thibaut Duparc
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Marcelo León
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Guillaume Combes
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Laure Frayssinhes
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Audren Fournel
- UMR 1220, IRSD, INSERM, INRA, ENVT, European Associated Laboratory NeuroMicrobiota (INSERM/UCL) University of Toulouse Toulouse France
| | - Anne Abot
- UMR 1220, IRSD, INSERM, INRA, ENVT, European Associated Laboratory NeuroMicrobiota (INSERM/UCL) University of Toulouse Toulouse France
| | - Bernard Masri
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| | - Nicol Parada
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Valeria Aguilera
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Claudio Aguayo
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
- Group of Research and Innovation in Vascular Health (GRIVAS Health) Chillan Chile
| | - Claude Knauf
- UMR 1220, IRSD, INSERM, INRA, ENVT, European Associated Laboratory NeuroMicrobiota (INSERM/UCL) University of Toulouse Toulouse France
| | - Marcelo González
- Group of Research and Innovation in Vascular Health (GRIVAS Health) Chillan Chile
- Vascular Physiology Laboratory, Department of Physiology, Faculty of Biological Sciences, and Department of Obstetrics and Gynecology, Faculty of Medicine Universidad de Concepción Concepción Chile
| | - Claudia Radojkovic
- Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy Universidad de Concepción Concepción Chile
| | - Laurent O. Martinez
- INSERM, UMR1048, Institute of Metabolic and Cardiovascular Diseases University of Toulouse, Paul Sabatier University Toulouse France
| |
Collapse
|
15
|
Verdier C, Ruidavets JB, Genoux A, Combes G, Bongard V, Taraszkiewicz D, Galinier M, Elbaz M, Ferrières J, Martinez LO, Perret B. Common p2y 13 polymorphisms are associated with plasma inhibitory factor 1 and lipoprotein(a) concentrations, heart rate and body fat mass: The GENES study. Arch Cardiovasc Dis 2019; 112:124-134. [PMID: 30600215 DOI: 10.1016/j.acvd.2018.09.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 08/07/2018] [Accepted: 09/10/2018] [Indexed: 12/13/2022]
Abstract
BACKGROUND The P2Y13 purinergic receptor regulates hepatic high-density lipoprotein uptake and biliary sterol secretion; it acts downstream of the membrane ecto-F1-adenosine triphosphatase, which generates extracellular adenosine diphosphate that selectively activates P2Y13, resulting in high-density lipoprotein endocytosis. Previous studies have shown that the serum concentration of the F1-adenosine triphosphatase inhibitor inhibitory factor 1 is negatively associated with cardiovascular risk. AIM To evaluate whether p2y13 genetic variants affect cardiovascular risk. METHODS Direct sequencing of the p2y13 coding and flanking regions was performed in a subcohort of 168 men aged 45-74 years with stable coronary artery disease and 173 control subjects from the GENES study. The two most frequent mutations, rs3732757 and rs1466684, were genotyped in 767 patients with coronary artery disease and 789 control subjects, and their association with cardiovascular risk markers was analysed. RESULTS Carriers of the rs3732757 261T and rs1466684 557G alleles represented 9% and 27.5% of the entire population, respectively. The allele frequencies were identical in patients with coronary artery disease and control subjects. The presence of 261T was associated with higher concentrations of plasma lipoprotein A-I and inhibitory factor 1, increased fat mass and a lower heart rate. Moreover, the proportion of patients with coronary artery disease with a pejorative systolic ankle-brachial index was lower in carriers of the 261T allele. In both populations, the 557G allele was associated with increased concentrations of lipoprotein(a), and an allele dose effect was observed. CONCLUSIONS Two frequent p2y13 variants are associated with specific bioclinical markers of cardiovascular risk. Although neither one of these variants appears to be related to the development of atherosclerotic disease, they may modulate the risk of additional cardiovascular complications.
Collapse
Affiliation(s)
- Céline Verdier
- Inserm, UMR 1048, Institute of Metabolic and Cardiovascular Diseases, 31432 Toulouse, France; Paul Sabatier University, University of Toulouse, 31330 Toulouse, France; Service de biochimie, Pôle Biologie, Hôpital Purpan, CHU de Toulouse, 31300 Toulouse, France
| | - Jean-Bernard Ruidavets
- Paul Sabatier University, University of Toulouse, 31330 Toulouse, France; Inserm, UMR 1027, épidémiologie et analyse en santé publique, 31000 Toulouse, France; Department of Cardiology, hôpital de Rangueil, CHU de Toulouse, 31400 Toulouse, France
| | - Annelise Genoux
- Inserm, UMR 1048, Institute of Metabolic and Cardiovascular Diseases, 31432 Toulouse, France; Paul Sabatier University, University of Toulouse, 31330 Toulouse, France; Service de biochimie, Pôle Biologie, Hôpital Purpan, CHU de Toulouse, 31300 Toulouse, France
| | - Guillaume Combes
- Inserm, UMR 1048, Institute of Metabolic and Cardiovascular Diseases, 31432 Toulouse, France; Paul Sabatier University, University of Toulouse, 31330 Toulouse, France; Service de biochimie, Pôle Biologie, Hôpital Purpan, CHU de Toulouse, 31300 Toulouse, France
| | - Vanina Bongard
- Paul Sabatier University, University of Toulouse, 31330 Toulouse, France; Inserm, UMR 1027, épidémiologie et analyse en santé publique, 31000 Toulouse, France; Department of Cardiology, hôpital de Rangueil, CHU de Toulouse, 31400 Toulouse, France
| | - Dorota Taraszkiewicz
- Department of Cardiology, hôpital de Rangueil, CHU de Toulouse, 31400 Toulouse, France
| | - Michel Galinier
- Department of Cardiology, hôpital de Rangueil, CHU de Toulouse, 31400 Toulouse, France
| | - Meyer Elbaz
- Inserm, UMR 1048, Institute of Metabolic and Cardiovascular Diseases, 31432 Toulouse, France; Paul Sabatier University, University of Toulouse, 31330 Toulouse, France; Department of Cardiology, hôpital de Rangueil, CHU de Toulouse, 31400 Toulouse, France
| | - Jean Ferrières
- Paul Sabatier University, University of Toulouse, 31330 Toulouse, France; Inserm, UMR 1027, épidémiologie et analyse en santé publique, 31000 Toulouse, France; Department of Cardiology, hôpital de Rangueil, CHU de Toulouse, 31400 Toulouse, France
| | - Laurent O Martinez
- Inserm, UMR 1048, Institute of Metabolic and Cardiovascular Diseases, 31432 Toulouse, France; Paul Sabatier University, University of Toulouse, 31330 Toulouse, France.
| | - Bertrand Perret
- Inserm, UMR 1048, Institute of Metabolic and Cardiovascular Diseases, 31432 Toulouse, France; Paul Sabatier University, University of Toulouse, 31330 Toulouse, France; Service de biochimie, Pôle Biologie, Hôpital Purpan, CHU de Toulouse, 31300 Toulouse, France
| |
Collapse
|
16
|
Genoux A, Picot M, Duparc T, Combes G, Vayssieres C, Perret B, Hamdi S, Martinez L. 184. High density lipoproteins lose their antioxidant protective effect during pre-eclampsia. Pregnancy Hypertens 2018. [DOI: 10.1016/j.preghy.2018.08.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Combes G, Barysz H, Garand C, Gama Braga L, Alharbi I, Thebault P, Murakami L, Bryne DP, Stankovic S, Eyers PA, Bolanos-Garcia VM, Earnshaw WC, Maciejowski J, Jallepalli PV, Elowe S. Mps1 Phosphorylates Its N-Terminal Extension to Relieve Autoinhibition and Activate the Spindle Assembly Checkpoint. Curr Biol 2018; 28:872-883.e5. [PMID: 29502948 PMCID: PMC5863767 DOI: 10.1016/j.cub.2018.02.002] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Revised: 01/15/2018] [Accepted: 02/01/2018] [Indexed: 12/29/2022]
Abstract
Monopolar spindle 1 (Mps1) is a conserved apical kinase in the spindle assembly checkpoint (SAC) that ensures accurate segregation of chromosomes during mitosis. Mps1 undergoes extensive auto- and transphosphorylation, but the regulatory and functional consequences of these modifications remain unclear. Recent findings highlight the importance of intermolecular interactions between the N-terminal extension (NTE) of Mps1 and the Hec1 subunit of the NDC80 complex, which control Mps1 localization at kinetochores and activation of the SAC. Whether the NTE regulates other mitotic functions of Mps1 remains unknown. Here, we report that phosphorylation within the NTE contributes to Mps1 activation through relief of catalytic autoinhibition that is mediated by the NTE itself. Moreover, we find that this regulatory NTE function is independent of its role in Mps1 kinetochore recruitment. We demonstrate that the NTE autoinhibitory mechanism impinges most strongly on Mps1-dependent SAC functions and propose that Mps1 activation likely occurs sequentially through dimerization of a “prone-to-autophosphorylate” Mps1 conformer followed by autophosphorylation of the NTE prior to maximal kinase activation segment trans-autophosphorylation. Our observations underline the importance of autoregulated Mps1 activity in generation and maintenance of a robust SAC in human cells. Mps1 autophosphorylation at the NTE promotes activity independent of localization NTE phosphorylation relieves an NTE-dependent autoinhibition Mps1 autophosphorylation at its NTE is essential for the SAC, but not congression
Collapse
Affiliation(s)
- Guillaume Combes
- Programme in Molecular and Cellular Biology, Faculty of Medicine, Université Laval, 1050 Avenue de la Médecine, Bureau 4633, Université Laval, Québec, QC G1V0A6, Canada; Axe of Reproduction, Mother and Youth Health, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1V 4G2, Canada
| | - Helena Barysz
- Wellcome Centre for Cell Biology, Institute of Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, UK
| | - Chantal Garand
- Axe of Reproduction, Mother and Youth Health, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1V 4G2, Canada
| | - Luciano Gama Braga
- Programme in Molecular and Cellular Biology, Faculty of Medicine, Université Laval, 1050 Avenue de la Médecine, Bureau 4633, Université Laval, Québec, QC G1V0A6, Canada; Axe of Reproduction, Mother and Youth Health, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1V 4G2, Canada
| | - Ibrahim Alharbi
- Programme in Molecular and Cellular Biology, Faculty of Medicine, Université Laval, 1050 Avenue de la Médecine, Bureau 4633, Université Laval, Québec, QC G1V0A6, Canada; Axe of Reproduction, Mother and Youth Health, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1V 4G2, Canada
| | - Philippe Thebault
- Axe of Reproduction, Mother and Youth Health, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1V 4G2, Canada
| | - Luc Murakami
- Axe of Reproduction, Mother and Youth Health, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1V 4G2, Canada
| | - Dominic P Bryne
- Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK
| | - Stasa Stankovic
- Department of Biological and Medical Sciences - Faculty of Health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, UK
| | - Patrick A Eyers
- Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK
| | - Victor M Bolanos-Garcia
- Department of Biological and Medical Sciences - Faculty of Health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, UK
| | - William C Earnshaw
- Wellcome Centre for Cell Biology, Institute of Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, UK
| | - John Maciejowski
- Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Prasad V Jallepalli
- Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Sabine Elowe
- Programme in Molecular and Cellular Biology, Faculty of Medicine, Université Laval, 1050 Avenue de la Médecine, Bureau 4633, Université Laval, Québec, QC G1V0A6, Canada; Axe of Reproduction, Mother and Youth Health, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1V 4G2, Canada.
| |
Collapse
|
18
|
Combes G, Alharbi I, Braga LG, Elowe S. Playing polo during mitosis: PLK1 takes the lead. Oncogene 2017; 36:4819-4827. [PMID: 28436952 DOI: 10.1038/onc.2017.113] [Citation(s) in RCA: 99] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Revised: 03/16/2017] [Accepted: 03/18/2017] [Indexed: 12/18/2022]
Abstract
Polo-like kinase 1 (PLK1), the prototypical member of the polo-like family of serine/threonine kinases, is a pivotal regulator of mitosis and cytokinesis in eukaryotes. Many layers of regulation have evolved to target PLK1 to different subcellular structures and to its various mitotic substrates in line with its numerous functions during mitosis. Collective work is starting to illuminate an important set of substrates for PLK1: the mitotic kinases that together ensure the fidelity of the cell division process. Amongst these, recent developments argue that PLK1 regulates the activity of the histone kinases Aurora B and Haspin to define centromere identity, of MPS1 to initiate spindle checkpoint signaling, and of BUB1 and its pseudokinase paralog BUBR1 to coordinate spindle checkpoint activation and inactivation. Here, we review the recent work describing the regulation of these kinases by PLK1. We highlight common themes throughout and argue that a major mitotic function of PLK1 is as a master regulator of these key kinases.
Collapse
Affiliation(s)
- G Combes
- Program in Molecular and Cellular biology, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada
- Axe of Reproduction, Mother and Youth Health, CHU de Québec Research Centre, Quebec City, Quebec, Canada
| | - I Alharbi
- Program in Molecular and Cellular biology, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada
- Axe of Reproduction, Mother and Youth Health, CHU de Québec Research Centre, Quebec City, Quebec, Canada
| | - L G Braga
- Program in Molecular and Cellular biology, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada
- Axe of Reproduction, Mother and Youth Health, CHU de Québec Research Centre, Quebec City, Quebec, Canada
| | - S Elowe
- Program in Molecular and Cellular biology, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada
- Axe of Reproduction, Mother and Youth Health, CHU de Québec Research Centre, Quebec City, Quebec, Canada
- Department of Pediatrics, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada
| |
Collapse
|
19
|
Genoux A, Lichtenstein L, Ferrières J, Duparc T, Bongard V, Vervueren PL, Combes G, Taraszkiewicz D, Elbaz M, Galinier M, Nassar B, Ruidavets JB, Perret B, Martinez LO. Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study. BMC Med 2016; 14:125. [PMID: 27553421 PMCID: PMC4994300 DOI: 10.1186/s12916-016-0672-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 08/10/2016] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Epidemiological and observational studies have established that high-density lipoprotein cholesterol (HDL-C) is an independent negative cardiovascular risk factor. However, simple measurement of HDL-C levels is no longer sufficient for cardiovascular risk assessment. Therefore, there is a critical need for novel non-invasive biomarkers that would display prognostic superiority over HDL-C. Cell surface ecto-F1-ATPase contributes to several athero-protective properties of HDL, including reverse cholesterol transport and vascular endothelial protection. Serum inhibitory factor 1 (IF1), an endogenous inhibitor of ecto-F1-ATPase, is an independent determinant of HDL-C associated with low risk of coronary artery disease (CAD). This work aimed to examine the predictive value of serum IF1 for long-term mortality in CAD patients. Its informative value was compared to that of HDL-C. METHOD Serum IF1 levels were measured in 577 male participants with stable CAD (age 45-74 years) from the GENES (Genetique et ENvironnement en Europe du Sud) study. Vital status was yearly assessed, with a median follow-up of 11 years and a 29.5 % mortality rate. Cardiovascular mortality accounted for the majority (62.4 %) of deaths. RESULTS IF1 levels were positively correlated with HDL-C (r s = 0.40; P < 0.001) and negatively with triglycerides (r s = -0.21, P < 0.001) and CAD severity documented by the Gensini score (r s = -0.13; P < 0.01). Total and cardiovascular mortality were lower at the highest quartiles of IF1 (HR = 0.55; 95 % CI, 0.38-0.89 and 0.50 (0.28-0.89), respectively) but not according to HDL-C. Inverse associations of IF1 with mortality remained significant, after multivariate adjustments for classical cardiovascular risk factors (age, smoking, physical activity, waist circumference, HDL-C, dyslipidemia, hypertension, and diabetes) and for powerful biological and clinical variables of prognosis, including heart rate, ankle-brachial index and biomarkers of cardiac diseases. The 10-year mortality was 28.5 % in patients with low IF1 (<0.42 mg/L) and 21.4 % in those with high IF1 (≥0.42 mg/L, P < 0.02). CONCLUSIONS We investigated for the first time the relation between IF1 levels and long-term prognosis in CAD patients, and found an independent negative association. IF1 measurement might be used as a novel HDL-related biomarker to better stratify risk in populations at high risk or in the setting of pharmacotherapy.
Collapse
Affiliation(s)
- Annelise Genoux
- Institute of Metabolic and Cardiovascular Diseases, I2MC, Inserm, UMR 1048, Toulouse, France
- Université de Toulouse, UMR1048, Toulouse, France
- CHU Toulouse, Toulouse University Hospital, Service de Biochimie, Pôle biologie, Hôpital de Purpan, Toulouse, France
| | - Laeticia Lichtenstein
- Institute of Metabolic and Cardiovascular Diseases, I2MC, Inserm, UMR 1048, Toulouse, France
- Université de Toulouse, UMR1048, Toulouse, France
| | - Jean Ferrières
- Department of Epidemiology, Health Economics and Public Health, Inserm, Université de Toulouse, CHU Toulouse, UMR1027, Toulouse, France
- CHU Toulouse, Toulouse University Hospital, Fédération de Cardiologie, Toulouse, France
| | - Thibaut Duparc
- Institute of Metabolic and Cardiovascular Diseases, I2MC, Inserm, UMR 1048, Toulouse, France
- Université de Toulouse, UMR1048, Toulouse, France
| | - Vanina Bongard
- Department of Epidemiology, Health Economics and Public Health, Inserm, Université de Toulouse, CHU Toulouse, UMR1027, Toulouse, France
| | - Paul-Louis Vervueren
- Department of Epidemiology, Health Economics and Public Health, Inserm, Université de Toulouse, CHU Toulouse, UMR1027, Toulouse, France
- CHU Toulouse, Toulouse University Hospital, Fédération de Cardiologie, Toulouse, France
| | - Guillaume Combes
- Institute of Metabolic and Cardiovascular Diseases, I2MC, Inserm, UMR 1048, Toulouse, France
- CHU Toulouse, Toulouse University Hospital, Service de Biochimie, Pôle biologie, Hôpital de Purpan, Toulouse, France
| | - Dorota Taraszkiewicz
- CHU Toulouse, Toulouse University Hospital, Fédération de Cardiologie, Toulouse, France
| | - Meyer Elbaz
- CHU Toulouse, Toulouse University Hospital, Fédération de Cardiologie, Toulouse, France
| | - Michel Galinier
- CHU Toulouse, Toulouse University Hospital, Fédération de Cardiologie, Toulouse, France
| | - Bertrand Nassar
- CHU Toulouse, Toulouse University Hospital, Service de Biochimie, Pôle biologie, Hôpital de Purpan, Toulouse, France
| | - Jean-Bernard Ruidavets
- Department of Epidemiology, Health Economics and Public Health, Inserm, Université de Toulouse, CHU Toulouse, UMR1027, Toulouse, France
| | - Bertrand Perret
- Institute of Metabolic and Cardiovascular Diseases, I2MC, Inserm, UMR 1048, Toulouse, France
- Université de Toulouse, UMR1048, Toulouse, France
- CHU Toulouse, Toulouse University Hospital, Service de Biochimie, Pôle biologie, Hôpital de Purpan, Toulouse, France
| | - Laurent O Martinez
- Institute of Metabolic and Cardiovascular Diseases, I2MC, Inserm, UMR 1048, Toulouse, France.
- Université de Toulouse, UMR1048, Toulouse, France.
| |
Collapse
|
20
|
Asghar A, Lajeunesse A, Dulla K, Combes G, Thebault P, Nigg EA, Elowe S. Bub1 autophosphorylation feeds back to regulate kinetochore docking and promote localized substrate phosphorylation. Nat Commun 2015; 6:8364. [PMID: 26399325 PMCID: PMC4598568 DOI: 10.1038/ncomms9364] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Accepted: 08/13/2015] [Indexed: 12/15/2022] Open
Abstract
During mitosis, Bub1 kinase phosphorylates histone H2A-T120 to promote centromere sister chromatid cohesion through recruitment of shugoshin (Sgo) proteins. The regulation and dynamics of H2A-T120 phosphorylation are poorly understood. Using quantitative phosphoproteomics we show that Bub1 is autophosphorylated at numerous sites. We confirm mitosis-specific autophosphorylation of a several residues and show that Bub1 activation is primed in interphase but fully achieved only in mitosis. Mutation of a single autophosphorylation site T589 alters kinetochore turnover of Bub1 and results in uniform H2A-T120 phosphorylation and Sgo recruitment along chromosome arms. Consequently, improper sister chromatid resolution and chromosome segregation errors are observed. Kinetochore tethering of Bub1-T589A refocuses H2A-T120 phosphorylation and Sgo1 to centromeres. Recruitment of the Bub1-Bub3-BubR1 axis to kinetochores has recently been extensively studied. Our data provide novel insight into the regulation and kinetochore residency of Bub1 and indicate that its localization is dynamic and tightly controlled through feedback autophosphorylation.
Collapse
Affiliation(s)
- Adeel Asghar
- Faculty of Medicine, Department of Molecular and Cellular Biology, Université Laval, Québec, Canada G1V 0A6.,Department of Reproduction, Mother and Youth Health, Centre de recherche du Centre Hospitalier Universitaire de Québec, Québec, Canada G1V 4G2
| | - Audrey Lajeunesse
- Faculty of Medicine, Department of Molecular and Cellular Biology, Université Laval, Québec, Canada G1V 0A6
| | - Kalyan Dulla
- ProQR Therapeutics N.V., Darwinweg 24, Leiden 2333 CR, The Netherlands
| | - Guillaume Combes
- Faculty of Medicine, Department of Molecular and Cellular Biology, Université Laval, Québec, Canada G1V 0A6.,Department of Reproduction, Mother and Youth Health, Centre de recherche du Centre Hospitalier Universitaire de Québec, Québec, Canada G1V 4G2
| | - Philippe Thebault
- Department of Reproduction, Mother and Youth Health, Centre de recherche du Centre Hospitalier Universitaire de Québec, Québec, Canada G1V 4G2
| | - Erich A Nigg
- Biozentrum, University of Basel, Klingelbergstrasse 50/70, Basel CH-4056, Switzerland
| | - Sabine Elowe
- Faculty of Medicine, Department of Molecular and Cellular Biology, Université Laval, Québec, Canada G1V 0A6.,Department of Reproduction, Mother and Youth Health, Centre de recherche du Centre Hospitalier Universitaire de Québec, Québec, Canada G1V 4G2
| |
Collapse
|
21
|
Lichtenstein L, Serhan N, Annema W, Combes G, Robaye B, Boeynaems JM, Perret B, Tietge UJF, Laffargue M, Martinez LO. Lack of P2Y13 in mice fed a high cholesterol diet results in decreased hepatic cholesterol content, biliary lipid secretion and reverse cholesterol transport. Nutr Metab (Lond) 2013; 10:67. [PMID: 24476490 PMCID: PMC4029266 DOI: 10.1186/1743-7075-10-67] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Accepted: 10/30/2013] [Indexed: 01/11/2023] Open
Abstract
Background The protective effect of HDL is mostly attributed to their metabolic function in reverse cholesterol transport (RCT), a process whereby excess cellular cholesterol is taken up from peripheral cells, processed in HDL particles, and later delivered to the liver for further metabolism and biliary secretion. Mechanistically, the purinergic P2Y13 ADP-receptor is involved in hepatic HDL endocytosis (i.e., uptake of both HDL protein + lipid moieties), which is considered an important step of RCT. Accordingly, chow-fed P2Y13 knockout (P2Y13-/-) mice exhibit lower hepatic HDL uptake, which translates into a decrease of hepatic free cholesterol content and biliary cholesterol and phospholipid secretion. Findings The aim of this study was to determine the effect of high cholesterol diet (HCD) in P2Y13-/- mice, in order to mimic high dietary cholesterol intake, which is a major cause of dyslipidemia in humans. As previously reported with chow-diet, HCD did not affect plasma lipid levels in P2Y13-/- compared with control mice but decreased hepatic free and esterified cholesterol content (p < 0.05, P2Y13-/- versus control). Interestingly, biliary lipid secretion and macrophages-to-feces RCT were more dramatically impaired in P2Y13-/- mice fed a HCD than chow-diet. HCD did not enhance atherosclerosis in P2Y13-/- compared with control mice. Conclusion This study demonstrates that high dietary cholesterol intake accentuated the metabolic phenotype of P2Y13-/- mice, with impaired hepatobiliary RCT. Although other animal models might be required to further evaluate the role of P2Y13 receptor in atherosclerosis, P2Y13 appears a promising target for therapeutic intervention aiming to stimulate RCT, particularly in individuals with lipid-rich diet.
Collapse
Affiliation(s)
- Laeticia Lichtenstein
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Nizar Serhan
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Wijtske Annema
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - Guillaume Combes
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Bernard Robaye
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Jean-Marie Boeynaems
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Bertrand Perret
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,CHU de Toulouse, Hôpital Purpan, Toulouse, France
| | - Uwe J F Tietge
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - Muriel Laffargue
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Laurent O Martinez
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France.,CHU de Toulouse, Hôpital Purpan, Toulouse, France
| |
Collapse
|
22
|
Genoux A, Ruidavets JB, Ferrières J, Combes G, Lichtenstein L, Pons V, Laffargue M, Taraszkiewicz D, Carrié D, Elbaz M, Perret B, Martinez LO. Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: the GENES study. J Lipid Res 2013; 54:2550-8. [PMID: 23794714 PMCID: PMC3735951 DOI: 10.1194/jlr.p036335] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2013] [Revised: 06/21/2013] [Indexed: 11/20/2022] Open
Abstract
HDL is strongly inversely related to cardiovascular risk. Hepatic HDL uptake is controlled by ecto-F1-ATPase activity, and potentially inhibited by mitochondrial inhibitor factor 1 (IF1). We recently found that IF1 is present in serum and correlates with HDL-cholesterol (HDL-C). Here, we have evaluated the relationship between circulating IF1 and plasma lipoproteins, and we determined whether IF1 concentration is associated with the risk of coronary heart disease (CHD). Serum IF1 was measured in 648 coronary patients ages 45-74 and in 669 matched male controls, in the context of a cross-sectional study on CHD. Cardiovascular risk factors were documented for each participant, including life-style habits and biological and clinical markers. In controls, multivariate analysis demonstrated that IF1 was independently positively associated with HDL-C and apoA-I (r = 0.27 and 0.28, respectively, P < 0.001) and negatively with triglycerides (r = -0.23, P < 0.001). Mean IF1 concentration was lower in CHD patients than in controls (0.43 mg/l and 0.53 mg/l, respectively, P < 0.001). In multivariate analyses, following adjustments on cardiovascular risk factors or markers, IF1 was negatively related to CHD (P < 0.001). This relationship was maintained after adjustment for HDL-C or apoA-I. This study identifies IF1 as a new determinant of HDL-C that is inversely associated with CHD.
Collapse
Affiliation(s)
- Annelise Genoux
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France
- Université de Toulouse III, UMR1048, Toulouse, 31300, France
- Service de Biochimie, Pôle biologie, hôpital de Purpan, CHU de Toulouse, Toulouse, 31000, France
| | | | - Jean Ferrières
- INSERM, U1027, Faculté de Médecine, Toulouse, 31073, France
- Service de Cardiologie, Pôle cardiovasculaire et métabolique, hôpital de Rangueil, CHU de Toulouse, Toulouse, 31000, France
| | - Guillaume Combes
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France
- Université de Toulouse III, UMR1048, Toulouse, 31300, France
| | - Laeticia Lichtenstein
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France
- Université de Toulouse III, UMR1048, Toulouse, 31300, France
| | - Véronique Pons
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France
- Université de Toulouse III, UMR1048, Toulouse, 31300, France
| | - Muriel Laffargue
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France
- Université de Toulouse III, UMR1048, Toulouse, 31300, France
| | | | - Didier Carrié
- Service de Cardiologie, Pôle cardiovasculaire et métabolique, hôpital de Rangueil, CHU de Toulouse, Toulouse, 31000, France
| | - Meyer Elbaz
- Service de Cardiologie, Pôle cardiovasculaire et métabolique, hôpital de Rangueil, CHU de Toulouse, Toulouse, 31000, France
| | - Bertrand Perret
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France
- Université de Toulouse III, UMR1048, Toulouse, 31300, France
- Service de Biochimie, Pôle biologie, hôpital de Purpan, CHU de Toulouse, Toulouse, 31000, France
| | - Laurent O. Martinez
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France
- Université de Toulouse III, UMR1048, Toulouse, 31300, France
| |
Collapse
|
23
|
Genoux A, Pons V, Radojkovic C, Roux-Dalvai F, Combes G, Rolland C, Malet N, Monsarrat B, Lopez F, Ruidavets JB, Perret B, Martinez LO. Mitochondrial inhibitory factor 1 (IF1) is present in human serum and is positively correlated with HDL-cholesterol. PLoS One 2011; 6:e23949. [PMID: 21935367 PMCID: PMC3173369 DOI: 10.1371/journal.pone.0023949] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2011] [Accepted: 07/28/2011] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Mitochondrial ATP synthase is expressed as a plasma membrane receptor for apolipoprotein A-I (apoA-I), the major protein component in High Density Lipoproteins (HDL). On hepatocytes, apoA-I binds to cell surface ATP synthase (namely ecto-F(1)-ATPase) and stimulates its ATPase activity, generating extracellular ADP. This production of extracellular ADP activates a P2Y(13)-mediated HDL endocytosis pathway. Conversely, exogenous IF1, classically known as a natural mitochondrial specific inhibitor of F(1)-ATPase activity, inhibits ecto-F(1)-ATPase activity and decreases HDL endocytosis by both human hepatocytes and perfused rat liver. METHODOLOGY/PRINCIPAL FINDINGS Since recent reports also described the presence of IF1 at the plasma membrane of different cell types, we investigated whether IF1 is present in the systemic circulation in humans. We first unambiguously detected IF1 in human serum by immunoprecipitation and mass spectrometry. We then set up a competitive ELISA assay in order to quantify its level in human serum. Analyses of IF1 levels in 100 normolipemic male subjects evidenced a normal distribution, with a median value of 0.49 µg/mL and a 95% confidence interval of 0.22-0.82 µg/mL. Correlations between IF1 levels and serum lipid levels demonstrated that serum IF1 levels are positively correlated with HDL-cholesterol and negatively with triglycerides (TG). CONCLUSIONS/SIGNIFICANCE Altogether, these data support the view that, in humans, circulating IF1 might affect HDL levels by inhibiting hepatic HDL uptake and also impact TG metabolism.
Collapse
Affiliation(s)
- Annelise Genoux
- INSERM, UMR1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Université de Toulouse, UPS, Toulouse, France
- CHU Toulouse, Hôpital Purpan, Toulouse, France
| | - Véronique Pons
- INSERM, UMR1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Université de Toulouse, UPS, Toulouse, France
| | - Claudia Radojkovic
- INSERM, UMR1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Université de Toulouse, UPS, Toulouse, France
| | - Florence Roux-Dalvai
- CNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale), Toulouse, France
| | - Guillaume Combes
- INSERM, UMR1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Université de Toulouse, UPS, Toulouse, France
| | - Corinne Rolland
- INSERM, UMR1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Université de Toulouse, UPS, Toulouse, France
| | - Nicole Malet
- INSERM, UMR1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Université de Toulouse, UPS, Toulouse, France
| | - Bernard Monsarrat
- CNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale), Toulouse, France
| | - Frédéric Lopez
- INSERM, UMR1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Université de Toulouse, UPS, Toulouse, France
| | | | - Bertrand Perret
- INSERM, UMR1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Université de Toulouse, UPS, Toulouse, France
- CHU Toulouse, Hôpital Purpan, Toulouse, France
| | - Laurent O. Martinez
- INSERM, UMR1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France
- Université de Toulouse, UPS, Toulouse, France
| |
Collapse
|
24
|
Genoux A, Pons V, Laffargue M, Combes G, Ruidavets JB, Ferrières J, Perret B, Martinez L. 170 MITOCHONDRIAL INHIBITORY FACTOR 1 (IF1) IS PRESENT IN HUMAN SERUM AND ITS LEVEL IS POSITIVELY ASSOCIATED TO HDL-C. ATHEROSCLEROSIS SUPP 2011. [DOI: 10.1016/s1567-5688(11)70171-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Fabre AC, Malaval C, Ben Addi A, Verdier C, Pons V, Serhan N, Lichtenstein L, Combes G, Huby T, Briand F, Collet X, Nijstad N, Tietge UJF, Robaye B, Perret B, Boeynaems JM, Martinez LO. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 2010; 52:1477-83. [PMID: 20830789 DOI: 10.1002/hep.23897] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]
Abstract
UNLABELLED A major atheroprotective functionality of high-density lipoproteins (HDLs) is to promote "reverse cholesterol transport" (RCT). In this process, HDLs mediate the efflux and transport of cholesterol from peripheral cells and its subsequent transport to the liver for further metabolism and biliary excretion. We have previously demonstrated in cultured hepatocytes that P2Y(13) (purinergic receptor P2Y, G protein-coupled, 13) activation is essential for HDL uptake but the potential of P2Y(13) as a target to promote RCT has not been documented. Here, we show that P2Y(13)-deficient mice exhibited a decrease in hepatic HDL cholesterol uptake, hepatic cholesterol content, and biliary cholesterol output, although their plasma HDL and other lipid levels were normal. These changes translated into a substantial decrease in the rate of macrophage-to-feces RCT. Therefore, hallmark features of RCT are impaired in P2Y(13)-deficient mice. Furthermore, cangrelor, a partial agonist of P2Y(13), stimulated hepatic HDL uptake and biliary lipid secretions in normal mice and in mice with a targeted deletion of scavenger receptor class B type I (SR-BI) in liver (hypomSR-BI-knockout(liver)) but had no effect in P2Y(13) knockout mice, which indicate that P2Y(13)-mediated HDL uptake pathway is independent of SR-BI-mediated HDL selective cholesteryl ester uptake. CONCLUSION These results establish P2Y(13) as an attractive novel target for modulating RCT and support the emerging view that steady-state plasma HDL levels do not necessarily reflect the capacity of HDL to promote RCT.
Collapse
Affiliation(s)
- Aurélie C Fabre
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 563, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
De Graef H, Ledrut J, Combes G. Recherches dans la série des pyrazolones XIe mémoire Action des N-halogénimides sur l'antipyrine et ses dérivés. ACTA ACUST UNITED AC 2010. [DOI: 10.1002/bscb.19520610702] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
27
|
Radojkovic C, Genoux A, Pons V, Combes G, de Jonge H, Champagne E, Rolland C, Perret B, Collet X, Tercé F, Martinez LO. Stimulation of Cell Surface F1-ATPase Activity by Apolipoprotein A-I Inhibits Endothelial Cell Apoptosis and Promotes Proliferation. Arterioscler Thromb Vasc Biol 2009; 29:1125-30. [DOI: 10.1161/atvbaha.109.187997] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Claudia Radojkovic
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - Annelise Genoux
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - Véronique Pons
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - Guillaume Combes
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - Hugo de Jonge
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - Eric Champagne
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - Corinne Rolland
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - Bertrand Perret
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - Xavier Collet
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - François Tercé
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| | - Laurent O. Martinez
- From the INSERM U563 (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), Département Lipoprotéines et Médiateurs Lipidiques, Toulouse, France; Université de Toulouse (C.R., A.G., V.P., G.C., E.C., C.R., B.P., X.C., F.T., L.O.M.), UPS, IFR150, IFR-BMT, Toulouse, France; the Departamento de Bioquímica Clínica e Inmunología (C.R.), Facultad de Farmacia, Universidad de Concepción, Concepción, Chile; Growth Factors Group (H.d.J.), MRC Centre, Cambridge, UK; the Division of
| |
Collapse
|
28
|
|
29
|
|